Arbutus Biopharma (ABUS) FCF Margin (2013 - 2026)
Arbutus Biopharma (ABUS) posted FCF Margin of 4.53% for Q1 2026, up 98.98% sequentially from 445.29% in Q4 2025, and up 75460.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) FCF Margin (2013 - 2026) Analysis & Trends
Arbutus Biopharma has reported FCF Margin for 14 years, with the latest figure at 4.53% in Q1 2026.
- Quarterly FCF Margin rose 75460.0% year-over-year to 4.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.95% (up 90401.0% YoY) and the FY2025 annual result came in at 281.45%, up 77238.0% from the prior year.
- FCF Margin grew to 4.53% in Q1 2026 per ABUS's latest filing, from 445.29% in the prior quarter.
- Over five years, FCF Margin peaked at 163.29% in Q1 2022 and troughed at 1548.62% in Q3 2024.
- A 5-year average of 556.75% and a median of 445.29% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin surged 101422 bps in 2022, then plunged 108026 bps in 2024.
- Over 5 years, FCF Margin stood at 274.2% in 2022, then tumbled by 194 bps to 806.15% in 2023, then grew by 18 bps to 660.8% in 2024, then soared by 33 bps to 445.29% in 2025, then surged by 99 bps to 4.53% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 4.53%, 445.29%, and 1099.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | -593.49% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -593.49% |
| Mar 31, 2026 | -4.53% |
| Dec 31, 2025 | -445.29% |
| Sep 30, 2025 | -1,099.62% |
| Jun 30, 2025 | -146.65% |
| Mar 31, 2025 | -759.13% |
| Dec 31, 2024 | -660.80% |
| Sep 30, 2024 | -1,548.62% |
| Jun 30, 2024 | -840.38% |
| Mar 31, 2024 | -1,265.67% |
| Dec 31, 2023 | -806.15% |
| Sep 30, 2023 | -468.36% |
| Jun 30, 2023 | -439.00% |
| Mar 31, 2023 | -410.02% |
| Dec 31, 2022 | -274.20% |
| Sep 30, 2022 | -315.57% |
| Jun 30, 2022 | -143.99% |
| Mar 31, 2022 | 163.29% |
| Dec 31, 2021 | -613.35% |
| Sep 30, 2021 | -480.72% |